Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07616154 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

StatusRecruiting
PhasePhase 2
Started2026-09
View on ClinicalTrials.gov ↗

Amendment history

2026-07-21
Study Status, Contacts/Locations v1
Recruitment opened
Study sitesdetails revised at 1 of 1 site
2026-05-27
Original filing
The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD. Primary Objective: \- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD. Secondary Objectives: * Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD. * Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD. * Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.
Trial Details
NCT Number NCT07616154
Lead Sponsor St. Jude Children's Research Hospital
Conditions Sickle Cell Disease
Enrollment 45 participants
Start Date 2026-09
Primary Completion 2034-09 (estimated)
Study Completion 2035-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-23